MEDI-6469

DB15306InvestigationalProtein Based Therapies

MEDI-6469 is a monoclonal antibody under investigation in clinical trial NCT02205333 (A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies).

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 4
Curator reviewed
Also known as: Agonistic anti-OX40 monoclonal antibody MEDI6469
Code names: MEDI-6469

Resolves to

Compound

UNIIAKV2GM43DDCAS1715924-11-0

Targets

P43489TNFRSF4

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with MEDI-6469, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account